Compounds and methods for modulating activation of NF-κB
AssigneeSignal Pharmaceuticals, LLC
InventorsAnthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
Life of this patent
Estimating the term…
Abstract
Compositions and methods for modulating the activation of nuclear factor κB (NF-κB) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated IκBα and/or IκBβ. Such compositions may be used for treating diseases associated with NF-κB activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
Claims5
A method for screening for an agent that modulates NF-κB activity, comprising the steps of:
- (a) contacting a candidate agent with a polypeptide comprising SEQ ID NO:
- 18, wherein the polypeptide enhances ubiquitination of phosphorylated IκB, under conditions and for a time sufficient to permit interaction between the polypeptide and candidate agent;
- and
- (b) subsequently evaluating the ability of the polypeptide to enhance ubiquitination of phosphorylated IκB, relative to the ability of the polypeptide to enhance ubiquitination of phosphorylated IκB in the absence of said candidate agent using a negative control, wherein said negative control is a mutant polypeptide consisting of SEQ ID NO:18, wherein F box residues 122-168 are deleted;
- and therefrom identifying an agent that modulates NF-κB activity.
Dependencies are inferred from the claim text.